Drug and country characteristics associated with global approval and launch of FDA-approved novel therapeutics

Health Affairs Scholar · Published 2026-07-01 · DOI 10.1093/haschl/qxag181

Free full text

Authors (8)

Mengyuan Fu, Joshua Wallach, Anthony D So, Harry Doernberg, Xiangyu Li, Xiaodong Guan, Reshma Ramachandran, Joseph Ross

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Fu, M., Wallach, J., So, A., et al. (2026). Drug and country characteristics associated with global approval and launch of FDA-approved novel therapeutics. Health Affairs Scholar. https://doi.org/10.1093/haschl/qxag181

Related articles

• Randomized communication nudges to increase primary care engagement among Medicaid enrollees in Maine · Health Affairs Scholar · 2026 · Same journal
• Over-the-counter emergency contraceptive sales before and after Dobbs : a difference-in-difference analysis of US retail data · Health Affairs Scholar · 2026 · Same journal
• Factors influencing FDA drug approval decisions beyond clinical trial evidence: a scoping review · Health Affairs Scholar · 2026 · Same journal
• The impact of Medicaid expansion on coverage among those lacking housing basics, 2010-2019 · Health Affairs Scholar · 2026 · Same journal
• Medicaid Payment Policies for Methadone Maintenance Treatment for Opioid Use Disorder, 2020-2025 · Health Affairs Scholar · 2026 · Same journal
• Employee preferences in health plan design: results from a national survey · Health Affairs Scholar · 2026 · Same journal
• Minimizing H.R.1-related Medicaid coverage disruptions for high-risk patients · Health Affairs Scholar · 2026 · Same journal
• Separation from the CDC and its consequences for the public health workforce: findings from the CDC WISE Survey · Health Affairs Scholar · 2026 · Same journal
• Universal Free School Meals and Medicaid Spending: Evidence from Linked Education and Claims Data in Arkansas · Health Affairs Scholar · 2026 · Same journal
• An evaluation of the US public–private Combating Antibiotic-Resistant Bacteria Accelerator (CARB-X) initiative · Health Affairs Scholar · 2026 · Same journal